
PG3733USW



REMARKS

Claims 1-2, 4-6 and 8 have been canceled by this amendment. Currently claims 3, 7, and 9-14 are pending in the application. The subject matter of Claims 1-2, 4-6 and 8 have been cancelled and rewritten as new Claims 9-14 in a format more acceptable to the Patent Office. Hence, there is no new matter. Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Respectfully submitted,

Bonnie L. Deppenbrock
Attorney for Applicants

Registration No.28,209

Date: 12/18/01 GlaxoSmithKline Corporate Intellectual Property Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709

Phone: 919-483-1577 Facsimile: 919-483-7988